Skip to main content
. 2022 May 17;7(21):17658–17669. doi: 10.1021/acsomega.2c00535

Figure 1.

Figure 1

Schematic representation of fibrotic cells carrying GF, TGF-β, and αVβ6 integrin receptors. The small molecules GSK3008348 and PLN-74809 are αVβ6 integrin antagonists that inhibit integrin binding to LAPm thus preventing the active TGF-β release and profibrotic signaling events; nintedanib inhibits the tyrosine kinase activity of GF receptors and prevents downstream intracellular signaling events.